RT Journal Article
SR Electronic
T1 Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.28.23285137
DO 10.1101/2023.01.28.23285137
A1 Zola Matuvanga, Trésor
A1 Mariën, Joachim
A1 Larivière, Ynke
A1 Osangir, Bernard
A1 Milolo, Solange
A1 Meta, Rachel
A1 Esanga, Emmanuel
A1 Maketa, Vivi
A1 Matangila, Junior
A1 Mitashi, Patrick
A1 Ahuka Mundeke, Steve
A1 Muhindo-Mavoko, Hypolite
A1 Muyembe Tamfum, Jean-Jacques
A1 Van Damme, Pierre
A1 Van geertruyden, Jean-Pierre
YR 2023
UL http://medrxiv.org/content/early/2023/01/30/2023.01.28.23285137.abstract
AB Introduction A serosurvey among health care providers (HCPs) and frontliners of an area previously affected by Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC) was conducted to assess the seroreactivity to Ebola virus antigens.Methods Serum samples were collected in a cohort of HCPs and frontliners (n=698) participants in the EBL2007 vaccine trial (December 2019 to October 2022). Specimens seroreactive for EBOV were confirmed using either the Filovirus Animal Nonclinical Group (FANG) ELISA or a Luminex multiplex assay.Results The seroreactivity to at least two EBOV-Mayinga (m) antigens was found in 10 (1.4%: 95% CI, 0.7-2.6) samples for GP-EBOV-m + VP40-EBOV-m, and 2 (0.3%: 95% CI, 0.0 - 1.0) samples for VP40-EBOV-m + NP-EBOV-m using the Luminex assay. Seroreactivity to GP-EBOV-Kikwit (k) was observed in 59 (8.5%: 95%CI, 6.5-10.9) samples using FANG ELISA.Conclusion In contrast to previous serosurveys, a low seroprevalence was found in the HCP and frontline population participating in the EBL2007 Ebola vaccine trial in Boende, DRC. This underscores the high need for standardized antibody assays and cutoffs in EBOV serosurveys to avoid the broad range of reported EBOV seroprevalence rates in EBOV endemic areas.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the EBOVAC3. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 800176 (IMI-EU).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The National Ethics Committee of the DRC Ministry of Health approved the study protocol of EBL2007I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript